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1. Introduction 
The concept of CYLD cutaneous syndrome was proposed by Rajan et al. in 2009 (Rajan et al., 
2009). The syndrome represents an uncommon autosomal dominant disease caused by a 
germline mutation in the cylindromatosis gene (CYLD) (Biggs PJ, et al. 1995). CYLD 
cutaneous syndrome is characterized by the development of multiple neoplasms originating 
from the skin appendages (Rajan et al., 2009). It includes three appendageal tumor 
predisposition syndromes; familial cylindromatosis (FC, MIM 132700), Brooke-Spiegler 
syndrome (BSS, MIM 605041), and multiple familial trichoepithelioma (MFT, MIM 601606) 
(Rajan et al., 2009). BSS is characterized by multiple skin appendage tumors such as 
cylindroma, trichoepithelioma, and spiradenoma. FC is typified by multiple cylindromas 
and MFT by multiple trichoepitheliomas. Here, we summarize current clinical and genetic 
recognition in CYLD cutaneous syndrome. 
2. CYLD cutaneous syndrome  
A genome search using two FC families identified strong evidence for linkage to the locus 
on chromosome 16q12-q13 (Biggs et al., 1995). Subsequently, germline mutations in the 
tumor suppressor CYLD gene were identified in individuals having FC (Bignell et al. 2000). 
A combination of genetic linkage analysis and loss of heterozygosity in 15 FC families 
showed only the linkage to the locus, providing no evidence for genetic heterogeneity 
(Takahashi et al. 2000). The germline mutations were then detected in individuals with BSS 
(HU et al., 2003; Poblete Gutiérrez et al., 2002) and MFT (Salhi et al., 2004; Zhang et al., 2004; 
Zheng et al., 2004). Affected family members with the same germline mutation in CYLD 
showed FC, BSS or MFT phenotypes, indicating the absence of genotype-phenotype 
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relationship (Fenske et al., 2000; Rajan et al., 2009; Young et al., 2006). The phenotypic 
diversity from mild type to severe turban tumor is present in the affected family members 
with CYLD cutaneous syndrome (Biggs et al., 1995; Oiso et al., 2004; Rajan et al., 2009; Young 
et al., 2006). Bowen et al. suggested that FC, BSS, and MTF represent phenotypic variation of 
a single entity (Bowen et al., 2005). Rajan et al. proposed the term, CYLD cutaneous 
syndrome, for unifying three skin appendage-associated disorders (Rajan et al., 2009).  
3. The function of CYLD  
In 2003, CYLD was shown as a deubiquitinating enzyme that negatively regulates nuclear 
factor-kappa B (NF-B) activation (Brummelkamp et al., 2003; Kovalenko et al., 2003; 
Trompouki et al., 2003; Wilkinson, 2003). NF-B is involved in controlling inflammation, the 
immune response, and apoptosis (Pasparakis, 2002). Nowadays, many different cellular 
functions have been ascribed to CYLD such as proliferation and cell cycle, Ca2+ channel 
signaling, survival and apoptosis, inflammation, T-cell development and activation, 
antiviral response, and spermatogenesis (Pasparakis, 2002).  
CYLD contains three cytoskeleton-associated protein-glycine-rich (CAP-Gly) domains, two 
proline-rich motifs, a tumor necrosis factor-alpha (TNF-) receptor-associated factor 2 
(TRAF2) binding site, and ubiquitin-specific proteases (USP) domain responsible for its 
deubiquitinases (DUB) activity (Harhaj et al., 2011; Pasparakis, 2002). The first two CAP-Gly 
domains mediate binding to microtubules (Gao et al., 2008; Wickström et al., 2010), and the 
third CAP-Gly domain regulates NEMO interactions. NEMO (also known as IκB kinase 
gamma (IKKγ)) is the regulatory subunit of the IκB kinase (IKK) (Yoshida et al., 2011). IKK 
plays crucial role in activating NF-κB in response to various inflammatory stimuli (Zheng et 
al., 2011). TRAF2 regulates activation of the c-Jun N-terminal kinase (JNK)/c-Jun and the 
inhibitor of IKK/ NF-κB signaling cascades in response to TNF-α stimulation (Zhang et al., 
2011). 
4. Conclusion 
CYLD cutaneous syndrome represents familial cylindromatosis, Brooke-Spiegler syndrome, 
and multiple familial trichoepithelioma. Further studies for elucidating the function of 
CYLD will focus on defining the multifunctional activities including tumor suppression for 
neoplasms from the skin appendages.  
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